EGFR mutation analysis on circulating free DNA in NSCLC: a single-center experience
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1432-1335
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
EGFR mutation analysis on circulating free DNA in NSCLC: a single-center experience ; volume:147 ; number:8 ; day:18 ; month:5 ; year:2021 ; pages:2301-2307 ; date:8.2021
Journal of cancer research and clinical oncology ; 147, Heft 8 (18.5.2021), 2301-2307, 8.2021
- Urheber
-
Ianza, Anna
Chicco, A. Di
Biagi, C.
Giudici, F.
Dicorato, A.
Guglielmi, A.
Variola, F.
Tomasi, S.
Roviello, G.
Generali, D.
Zanconati, F.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00432-021-03658-8
- URN
-
urn:nbn:de:101:1-2021101010562358864938
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:35 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Ianza, Anna
- Chicco, A. Di
- Biagi, C.
- Giudici, F.
- Dicorato, A.
- Guglielmi, A.
- Variola, F.
- Tomasi, S.
- Roviello, G.
- Generali, D.
- Zanconati, F.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Predicting EGFR mutation, ALK rearrangement, and uncommon EGFR mutation in NSCLC patients by driverless artificial intelligence: a cohort study
Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC
The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis
Therapie des fortgeschrittenen NSCLC – Erlotinib jetzt zur Erstlinientherapie bei Patienten mit EGFR-Mutation zugelassen
Deciphering mechanisms of acquired T790M mutation after EGFR inhibitors for NSCLC by computational simulations
Machine learning-based radiomics strategy for prediction of acquired EGFR T790M mutation following treatment with EGFR-TKI in NSCLC
EGFR exon 20 insertion mutations in NSCLC
Sulforaphane attenuates EGFR signaling in NSCLC cells
Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib
The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment
Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Predicting EGFR mutation, ALK rearrangement, and uncommon EGFR mutation in NSCLC patients by driverless artificial intelligence: a cohort study
Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC
The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis
Therapie des fortgeschrittenen NSCLC – Erlotinib jetzt zur Erstlinientherapie bei Patienten mit EGFR-Mutation zugelassen
Deciphering mechanisms of acquired T790M mutation after EGFR inhibitors for NSCLC by computational simulations
Machine learning-based radiomics strategy for prediction of acquired EGFR T790M mutation following treatment with EGFR-TKI in NSCLC
EGFR exon 20 insertion mutations in NSCLC
Sulforaphane attenuates EGFR signaling in NSCLC cells
Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib
The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment
Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Predicting EGFR mutation, ALK rearrangement, and uncommon EGFR mutation in NSCLC patients by driverless artificial intelligence: a cohort study
Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC
The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis
Therapie des fortgeschrittenen NSCLC – Erlotinib jetzt zur Erstlinientherapie bei Patienten mit EGFR-Mutation zugelassen
Deciphering mechanisms of acquired T790M mutation after EGFR inhibitors for NSCLC by computational simulations
Machine learning-based radiomics strategy for prediction of acquired EGFR T790M mutation following treatment with EGFR-TKI in NSCLC
EGFR exon 20 insertion mutations in NSCLC
Sulforaphane attenuates EGFR signaling in NSCLC cells
Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib